RxDoctor Payments Data

Curran Emeruwa, MD

Urology · Mount Vernon, WANPI 1558719609

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 22.5%.

$12,170in general payments, 2019–2025

Across 194 payments — averaging $62.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Procept Biorobotics Corporation$2K
  • Coloplast$2K
  • Medtronic$2K
  • Teleflex LLC$772
  • Myriad Genetic Laboratories, Inc.$325
  • plus $2K from 34 others

What the payments were for

  • Consulting fees$3083%
  • Travel & lodging$6,31352%
  • Food & beverage$5,54946%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,170 in reported general payments places this provider in the 85th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$56,488
Medicare patients
221
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron58$34,506
GemtesaVibegron48$27,986
Tamsulosin Hcl151$2,459
Estradiol31$2,331
Oxybutynin Chloride ErOxybutynin Chloride69$917
Solifenacin Succinate39$889
Finasteride73$821
NitrofurantoinNitrofurantoin Macrocrystal13$571
Potassium Citrate ErPotassium Citrate13$484
Cephalexin26$435
Tolterodine Tartrate ErTolterodine Tartrate18$359
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$332
Ciprofloxacin Hcl31$181
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$94
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$86$34,50658 claims
Sumitomo Pharma America, Inc.Gemtesa$256$27,98648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Washington.

Other urology in Mount Vernon

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →